Concomitant β-blocker therapy is associated with a lower occurrence of ventricular arrhythmias in patients with decompensated heart failure

Journal of Cardiac Failure

Volumn 8, Issue 2, 2002, Pages 79-85

  Aronson, Doron ^a,b   Burger, Andrew J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Congestive heart failure; Ventricular arrhythmias; adrenergic blockers

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DOBUTAMINE; NESIRITIDE; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; SYMPATHETIC TONE;

EID: 0036095631     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2002.32946     Document Type: Article

References (28)

1. Primary prevention of sudden cardiac death in heart failure: Will the solution be shocking?
2. Location of death (in-hospital or out-of-hospital) and type of death (arrhythmic, nonarrhythmic, noncardiac) after inducible sustained ventricular tachyarrhythmias after syncope, sustained ventricular tachycardia, or nonfatal cardiac arrest (the ESVEM trial)
3. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
4. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) 11): A randomised trial
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
6. Additive beneficial effects of beta-blockers to angiotens-inconverting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study
7. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction
8. Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death
9. Prognosis in severe heart failure: Relation to hemodynamic measurements and ventricular ectopic activity
10. Ventricular arrhythmias in severe heart failure: Incidence, significance, and effectiveness of antiarrhythmic therapy
11. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases
12. Sudden death recorded during Holter monitoring
13. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: Double-blind, randomized, placebocontrolled study
14. Effect of carvedilol on survival in severe chronic heart failure
15. Importance of beta blockade in the therapy of serious ventricular arrhythmias
16. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
17. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry of Studies of Left Ventricular Dysfunction
18. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-Heart)
19. Beta adrenergic blockade in the treatment of sustained ventricular tachycardia or ventricular fibrillation
20. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias
21. Sympathetic stimulation and arrhythmias
22. Effects of bisoprolol on heart rate variability in heart failure
23. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure
24. Changes in spontaneous variability of ventricular ectopic activity as a function of time in patients with chronic arrhythmias
25. The changing base line of complex ventricular arrhythmias. A new consideration in assessing long-term antiarrhythmic drug therapy
26. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: Analysis of the Cardiac Arrhythmia Suppression Trial
27. Events in the cardiac arrhythmia suppression trial: Baseline predictors of mortality in placebo-treated patients
28. Prediction of cardiac death in patients with a very low ejection fraction after myocardial infarction: A Cardiac Arrhythmia Suppression Trial (CAST) study